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ABSTRACT 
Objective: The purpose of the study was to estimate the pharmacokinetic parameters and calculate the precision (%RMSE) of the predicted lithium 
concentration equation.  
Methods: This research was studied from blood Lithium levels of Children who had visited Yuwaprasart Waithayopathum Child Psychiatric 
Hospital from 31 December 2009-1 January 2011 The accuracy and precision of the equation were evaluated by the mathematical principle. The 
assist package software (WIN-NONLIN) was used to create pharmacokinetic parameters.  
Results: Twenty-nine patients were recruited. The characteristics (mean+SD) presented as the following; age = 15.79+2.64 y, weight = 69.75+22.28 
kg and the daily dose = 858.62+274.53 mg. The trough Lithium concentrations (mean+SD) = 0.56+19 mg/l. The kinetic parameter (Mean+SD) 
presented as the following; t1/2
Conclusion: In conclusion, the modified Yukawa equation may be used for the prediction of lithium concentration with 6.39% RMSE. 
 =7.23+3.38 hr., ke =0.12+0.07 hr-1, Vd = 48.83+15.60 L, AUC0-12 =11.01+5.61 mg x hr/l. The population 
pharmacokinetic parameters; ke, and AUC (0-∞) = 0.151 hr-1 and 169.81, mg x hr./l respectively. The modified equation from Yukawa for lithium 
clearance calculation and prediction lithium concentrations were CL (mL/min) = [36.5+(0.242x BW (kg)-7.79]/Scr (mg/dL) and lithium 
concentration (mg/l) = 4 x Dose (mg)/CL (mL/min)x73.89, respectively with 6.39 %RMSE (test for 20 patients data).  
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Lithium is the drug of choice in treating patients with mood 
disorders, especially in children [1-3]. However, the difficulty for 
drug use is adverse drug reactions [4-7] that needed to monitor 
serum drug concentrations [8-13]. Yuwaprasart Waithayopathum 
Child Psychiatric Hospital which one of the hospital that responsible 
for caring child psychiatric disorders patient, for example; autistic 
child also use lithium. While lithium prescribing is most common in 
this group, it has a problem of initiative lithium dosing design and 
monitoring. The application of the individual pharmacokinetic 
model for dosing adjustment by estimation pharmacokinetic 
parameters in individualized patients will be useful for lithium 
therapy monitoring.  
Therefore, the aim of the study is to estimate the pharmacokinetic 
parameters and calculate the precision (% RMSE) of the predicted 
lithium concentration equation in child psychiatric patients.  
MATERIALS AND METHODS 
Population 
The information of serum lithium concentration in children less than 
18 y who used lithium treatment in Yuwaprasart Waithayopathum 
Child Psychiatric Hospital was collected since 1 January 2009 to 31 
December 2011. 
Inclusion criteria 
The information of the following patients was used. 
1. Patients who aged less than 18 y old. 
2. Patients who used lithium continuously more than 1 w. 
3. Patients who had information of renal and hepatic laboratory 
examination values. 
4. Patients who had good compliance of drug therapy. 
Exclusion criteria 
Patients who had in-completed information such as laboratory 
values, drugs co-administration therapy. 
Research design 
The research design in this study was retrospective. The information 
was collected from children who received Lithium treatment from 
Yuwaprasart Waithayopathum Child Psychiatric Hospital during1 
January 2009 to 31 December 2011. The accuracy and precision of the 
equation were evaluated was evaluated based on the mathematical 
principle, and WIN-NONLIN program (with authorized code 
PHXWNL092) was used for calculation of the pharmacokinetic 
parameters of the population. This research was approved by the ethical 
committee of the hospital. (Reg. no. 0 07). 
Data analysis 
The information was analyzed by Excel program version 2013. The 
data presented in percentage, mean and standard deviation. The 
percent of Root mean square errors (% RMSE) was used for 
evaluating the precision of the equation, and Student-paired t-test 
statistic was used for comparison of predicted and observed serum 
lithium concentrations with the level of significance equal to 0.05. 
RESULTS 
Patient characteristic 
Twenty-nine patients information were collected as present in table 1. 
From the results, the mean age of participants was 16 y with the average 
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weight of 70 kg. The mean lithium dose was 900 mg/day. The serum 
lithium concentration (mean+SD) was 0.56+0.19 mg/l. All patients had 
normal serum creatinine (mean+SD) was 0.60+0.19 mg/dl.  
The number of patients who had serum lithium within therapeutic 
range (0.6-1.2 mg/l) was 13 (44.82%). While there were 16 patients 
(55.18%) had serum lithium outside therapeutic range.  
According to use the win-nonlin program to estimate population 
pharmacokinetics parameters and individual pharmacokinetics 
parameters via mathematical formulations, the individual patients’ 
values were presented in table 2 with population value was shown 
below the table. In addition, lithium clearance and predicted serum 
lithium concentrations of patients were presented in table 3. With 
the modified Yugawa equation with adjusted by measurement unit 




) = [36.5 +









) = 4 x 
Dose(mg)
CL (ml/min)
 x 73.89 
*73.89 is the molecular weight of lithium carbonate 
The lithium clearance and predicted serum lithium concentration 
from 20 patients who had completed data calculated from the above 
equation illustrated in table 4. Then the determination precision of 
estimation steady-state serum lithium concentration by comparison 
of observed value is available in table 5. The graph between observed 
serum lithium concentration and predicted serum lithium 
concentration demonstrated in fig. 1.  
The distribution of serum lithium concentration by lithium dose was 
presented in fig. 2 and 3, respectively.  
The distribution of calculated pharmacokinetic parameters compared 
with mean were explained by the graph in fig. 4-8. 
 
Table 1: Patients’ characteristics 
No Age (y) Weight (kg) lithium dose (mg) Serum lithium concentration (mg/l) Serum creatinine (mg/dl) 
1 15 74.0 900 0.49 NA 
2 15 51.0 1200 0.76 0.5 
3 14 68.0 900 0.7 0.7 
4 18 44.0 600 0.59 0.4 
5 17 118.0 1200 0.49 0.7 
6 17 65.0 900 0.32 NA 
7 16 70.0 900 0.54 0.5 
8 24 92.4 900 0.55 0.5 
9 15 51.0 1200 0.76 0.5 
10 14 49.0 900 0.6 NA 
11 15 56.0 900 0.8 0.5 
12 14 71.0 1200 0.73 NA 
13 14 54.0 300 0.5 NA 
14 13 57.5 300 0.58 0.6 
15 14 65.0 600 0.1 0.49 
16 17 93.4 600 0.64 0.8 
17 15 58.0 300 0.16 0.6 
18 8 38.0 600 0.39 0.3 
19 15 50.0 900 0.8 NA 
20 18 78.0 1200 0.78 0.8 
21 19 125.0 600 0.29 NA 
22 16 65.0 900 0.65 0.5 
23 19 62.0 900 0.63 0.2 
24 15 62.5 900 0.42 NA 
25 16 118.0 1200 0.49 0.7 
26 15 75.0 900 0.77 NA 
27 17 88.0 900 0.75 0.8 
28 17 77.0 1200 0.47 1 
29 16 47.0 900 0.49 0.4 
Mean 15.7 69.8 859 0.56 0.6 
SD 2.6 22.28 274 0.19 0.19 
 
 
Fig. 1: Graph of observed steady-state serum lithium concentration (Css observed, mg/l) and predicted serum lithium from the modified 
Yukawa equation. (C predicted) 
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Table 2: The estimation of pharmacokinetic parameters 
No. t1/2 (h) ke (h) Vd (L) AUC (0-12) ( mg h/l) 
1 NA NA 51.80 NA 
2 5.02 0.14 35.70 14.62 
3 8.52 0.08 47.60 13.95 
4 3.62 0.19 30.80 6.10 
5 11.66 0.06 82.60 14.67 
6 NA NA 45.50 NA 
7 6.20 0.11 49.00 9.86 
8 7.31 0.09 64.68 8.81 
9 5.02 0.14 35.70 14.62 
10 NA NA 34.30 NA 
11 5.36 0.13 39.20 10.65 
12 NA NA 49.70 NA 
13 NA NA 37.80 NA 
14 6.54 0.11 40.25 4.22 
15 5.79 0.12 45.50 6.62 
16 11.77 0.06 65.38 9.35 
17 6.58 0.11 40.60 4.21 
18 2.43 0.29 26.60 4.75 
19 NA NA 35.00 NA 
20 10.60 0.07 54.60 20.17 
21 NA NA 87.50 NA 
22 5.91 0.12 45.50 10.13 
23 2.29 0.30 43.40 4.12 
24 NA NA 43.75 NA 
25 11.66 0.06 82.60 14.67 
26 NA NA 52.50 NA 
27 11.38 0.06 61.60 14.40 
28 13.15 0.05 53.90 25.35 
29 3.79 0.18 32.90 8.98 
Mean 7.23 0.12 48.83 11.01 
SD 3.38 0.07 15.60 5.61 
NA= not available, the population pharmacokinetic parameters, the population pharmacokinetic parameters as shown below, ke (h-1) = 0.151429 
AUC (0-∞) (mghr/l) = 169.8113 
 
Table 3: Lithium clearance and predicted serum lithium concentration 
No. lithium clearance (ml/min) Predicted lithium concentration (mg/l) 
2 82.10 0.79 
3 64.52 0.76 
4 98.40 0.33 
5 81.81 0.79 
7 91.30 0.53 
8 102.14 0.48 
9 82.10 0.79 
11 84.52 0.58 
14 71.04 0.23 
15 90.69 0.36 
16 64.14 0.51 
17 71.24 0.23 
18 126.35 0.26 
20 59.48 1.09 
22 88.88 0.55 
23 218.57 0.22 
25 81.81 0.79 
27 62.51 0.78 
28 47.34 1.37 
29 100.21 0.49 
Mean 88.46 0.60 
SD 35.51 0.30 
 
 
Fig. 2: The distribution of serum lithium concentration (mg/l) versus dose 
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Table 4: Observed serum lithium concentration and predicted serum lithium concentration 
No. Observed serum lithium concentration (ml/min) Predicted lithium concentration (mg/l) Difference 
2 0.76 0.79 0.03 
3 0.70 0.76 0.06 
4 0.59 0.33 -0.26 
5 0.49 0.79 0.30 
7 0.54 0.53 -0.01 
8 0.55 0.48 -0.07 
9 0.76 0.79 0.03 
11 0.80 0.58 -0.22 
14 0.58 0.23 -0.35 
15 0.10 0.36 0.26 
16 0.64 0.51 -0.13 
17 0.16 0.23 0.07 
18 0.39 0.26 -0.13 
20 0.78 1.09 0.31 
22 0.65 0.55 -0.10 
23 0.63 0.22 -0.41 
25 0.49 0.79 0.30 
27 0.75 0.78 0.03 
28 0.47 1.37 0.90 
29 0.49 0.49 0.00 
%RMSE 0.0639 (6.39) 
t-test (p-value) 0.72 
 
 
Fig. 3: The graph of serum lithium concentrations (mg/l) versus dose (mg) 
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Fig. 4: The distribution of the volume distribution of lithium (L) 
 
 




Fig. 6: The distribution half-life of lithium (h) 
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Fig. 7: The distribution of lithium clearance (ml/min) 
 
 
Fig. 8: The distribution of area under the concentration-time curve at 0-12 h (AUC) of lithium (mg h/l) 
 
DISCUSSION 
The results from this study demonstrated that the modified Yukawa 
equation can use to predict serum lithium concentration with 
93.61% accuracy (error 6.39%).  It is not statistically significant 
differences (p=0.72) between observed and predicted serum lithium 
concentration. However, the variations among this group also found. 
The reason is because the various factors of patients, especially 
weight. Comparison with the previous report of the population 
clearance value found that this study had more lithium clearance 
than the previous report (10-40 ml/min) [13]. Therefore, using 
lithium dose beyond population clearance may result in treatment 
failure. Motoki et al. [14] found that Yukawa equation produced 
90.44% accuracy (error 9.56%) in prediction lithium clearance. 
However, when the modified Yukawa equation in Thai subject study 
was tested in Suwan P. study. The accuracy of this equation was 
92.05% (error 7.95%). It is quite similar to this study which found 
93.6% accuracy of modified Yukawa equation (error 6.39%). 
Therefore, the modified Yukawa equation in this study may 
appropriate for lithium dose calculation in children population.  
Other mathematical models were reviewed [15-32]. The model that 
study in Thai population only established in Suwan P. study [26] and 
the results found that the modified Yukawa could be used for lithium 
clearance estimation in an Adult Thai population with good 
precision. Therefore, Yukawa equation was chosen to modify in this 
study for children population. Cornelia et al. [33] applied the 
pharmacokinetics and pharmacodynamics knowledge for find 
appropriate lithium dosage adjustment in children. However, the 
research design was retrospective data collection, and there was a 
limitation in the application of pharmacodynamics parameter to the 
present study because of incomplete data. Since the 
pharmacodynamics parameter of Cornelia et al. study was Yong 
Mania Rating Scale and the hospital setting in this study did not use 
for routine work. Another discussion point is in Cornelia et al. study, 
it was focus only in children with bipolar disorders which is a 
difference from this study. Therefore, the results from Cornelia et al. 
may not apply in the wider group of children with other 
psychological disorder as this study. The further study is needed.  
According to there has been limited use of Lithium in psychiatric 
patients, especially in children in a healthcare setting. Therefore, 
leading this study had some limitation in term of "sample size". In 
addition, in-completed data through retrospective design were 
available. Moreover, it takes time and lots of expenditure if the 
prospective randomized design will be conducted.  
CONCLUSION 
The modified Yukawa equation with use to calculate Lithium 
clearance as the following CL (ml/min) = [36.5+(0.242x BW (kg)-
7.79]/Scr (mg/dl).  
This modified clearance equation can use to calculate serum lithium 
concentration as the following equation with % %RMSE = 6.39. 
Tewthanom et al. 
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